Impact of hypertension and antihypertensive treatment off organ damage

American Journal of Cardiology

Volumn 84, Issue 2 A, 1999, Pages 18-24

  Zanchetti, Alberto ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b ISTITUTO AUXOLOGICO ITALIANO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; NIFEDIPINE; RAMIPRIL; TELMISARTAN; VERAPAMIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CONFERENCE PAPER; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DOSE RESPONSE; ECHOCARDIOGRAPHY; GLOMERULOSCLEROSIS; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; INJURY; KIDNEY INJURY; MORBIDITY; MORTALITY; NONHUMAN; ORGAN; PRIORITY JOURNAL; PROTEINURIA; RAT;

EID: 0033595119     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9149(99)00364-1     Document Type: Conference Paper

References (26)

1. Zanchetti A. Goals of antihypertensive treatment prevention of cardiovascular events and prevention of organ damage . Blood Pressure. 1:1992;205-211.
2. 1993 Guidelines for the management of mild hypertension memorandum from a World Health Organization/International Society of Hypertension meeting . J Hypertens. 11:1993;905-918.
3. The sixth report of the Joint National Committee on Prevention, Detection, and Treatment of High Blood Pressure (JNC VI). Arch Intern Med. 157:1997;2413-2446.
4. 1999 World Health Organization/International Society of Hypertension guidelines for the management of hypertension . J Hypertens. 17:1999;151-183.
5. Devereux R.B., Pini R., Aurigemma G.F., Roman M.J. Measurement of left ventricular mass methodology and expertise . J Hypertens. 15:1997;801-809.
6. Wikstrand J. Calculation of left ventricular mass in man - a comment. J Hypertens. 15:1997;811-813.
7. Zanchetti A. A welcome debate on how to measure the left ventricular mass. [Editorial]. J Hypertens. 15:1997;799.
8. Korner P.I., Jennings G.L. Assessment of prevalence of left ventricular hypertrophy in hypertension. J Hypertens. 16:1998;715-723.
9. Levy D., Garrison R.J., Savage D.D., Kannel W.B., Castelli W.P. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 322:1990;1561-1566.
10. Koren M.J., Devereux R.B., Casale P.N., Savage D.D., Laragh J.H. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med. 114:1991;345-352.
11. Dahlöf B., Pennert K., Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients a meta-analysis of 109 treatment studies . Am J Hypertens. 5:1992;95-110.
12. Schmieder R.E., Schlaich M.P. Comparison of therapeutic studies on regression of left ventricular hypertrophy. Adv Exp Med Biol. 432:1997;191-198.
13. Agabiti-Rosei E., Ambrosioni E., Dal Palù C., Muiesan M.L., Zanchetti A. ACE inhibitor ramipril is more effective than the β-blocker atenolol in reducing left ventricular mass in hypertension results of the RACE (ramipril cardioprotective evaluation) study . J Hypertens. 13:1995;1325-1334.
14. Bohm M., Lee M., Kreutz R., Kim S., Schinke M., Djavidani B., Wagner J., Kaling M., Wienen W., Bader M., Ganten D. Angiotensin II receptor blockade in TGR (mREN2)27 effects of renin-angiotensin-system gene expression and cardiovascular functions . J Hypertens. 13:1995;891-899.
15. 1 receptor blockade on blood pressure and the renin angiotensin system in spontaneously hypertensive rats of the stroke prone strain. Clin Exp Hypertens. 20:1998;205-221.
16. Zanchetti A. Intermediate endpoints for atherosclerosis in hypertension. Blood Press. 6:(suppl 2):1997;97-102.
17. Zanchetti A., Agabiti-Rosei E., Dal Palù C., Leonetti G., Magnani B., Pessina A. The Verapamil in Hypertension and Atherosclerosis Study (VHAS) results of long-term randomized treatment with either verapamil or chlorthalidone on carotid intima-media thickness . J Hypertens. 16:1998;1667-1676.
18. Zanchetti A., Bond M.G., Hennig M., Neiss A., Mancia G., Dal Palù C., Hansson L., Magnani B., Rahn K.H., Reid J., Rodicio J., Safar M., Eckes L., Ravinetto R. Risk factors associated with alterations in carotid intima-media thickness in hypertension baseline data from the European Lacidipine Study on Atherosclerosis . J Hypertens. 16:1998;949-961.
19. O'Leary D.H., Polak J.F., Kronmal R.A., Manolio T.A., Burke G.L., Wolfson S.K. Jr. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults: Cardiovascular Health Study Collaborative Research Group. N Engl J Med. 340:1999;14-22.
20. Klag M.J., Whelton P.K., Randall B.L., Neaton J.D., Brancati F.L., Ford C.E., Schulman N.B., Stamler J. Blood pressure and end-stage renal disease in men. N Engl J Med. 334:1996;13-18.
21. Shulman N.B., Ford C.E., Hall W.D., Blaufox M.D., Simon D., Langford H.G., Schneider K.A. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Hypertension. 13:(suppl I):1989;I80-I93.
22. Zanchetti A., Hansson L. The incidence of cardiovascular events in the hypertensive patients of the Hypertension Optimal Treatment (HOT) study effects of additional risk factors . (Abstr.) J Hypertens. 17:(suppl 3):1999;S86-S87.
23. Samuelsson O., Wilhelmsen L., Elmfeldt D., Pennert K., Wedel H., Wikstrand J., Berglund G. Predictors of cardiovascular morbidity in treated hypertension results from the primary prevention trial in Göteborg, Sweden . J Hypertens. 3:1985;167-176.
24. Bohlen L., de Courten M., Weidmann P. Comparative study of the effect of ACE inhibitors and other antihypertensive agents on proteinuria in diabetic patients. Am J Hypertens. 7:1994;84S-92S.
25. Hansson L., Zanchetti A., Carruthers S.G., Dahlöf B., Elmfeldt D., Julius S., Menard J., Rahn K.H., Wedel H., Westerling S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension principal results of the Hypertension Optimal Treatment (HOT) randomised trial . Lancet. 351:1998;1755-1762.
26. Nielsen S., Dollerup J., Nielsen B., Jensen H.A., Mogensen C.E. Losartan reduces albuminuria in patients with essential hypertension an enalapril controlled 3 months study . Nephrol Dial Transplant. 12:1997;19-23.